Jill Feldman: The future of lung cancer screening (early detection) is bright 

Jill Feldman shared on X:

“The future of lung cancer screening (early detection) is bright. Jeff Yang talks about the impact ALCSI is having across collegiate chapters across the US, including the Plus One campaign at ACS National Lung Cancer Roundtable.

Thank you Jeff and team for raising awareness and changing the lung cancer narrative!”

Source: Jill Feldman/X

Jill Feldman is a lung cancer patient and advocate. She is the Co-Founder EGFR Resisters, an advocacy group of EGFR positive lung cancer patients who are resistant to targeted treatment. She is the Past President of the LUNGevity Foundation, Deputy Chair of IASLC’s patient advisory board and a member of The Chicago Institute of Translational Medicine’s patient advisory board.

Jill is a member of the programmatic panel for the Department of Defense Lung Cancer Research Program, a planning committee member on IASLC’s North America Conference on Lung cancer and as a member of the the ECOG-ACRIN Research Group’s patient advocate committee and thoracic committee.